Harmony Biosciences (HRMY) Tops Q4 EPS by 39c ; Offers Guidance

Harmony Biosciences (NASDAQ: HRMY) reported Q4 EPS of $1.08, $0.39 better than the analyst estimate of $0.69. Revenue for the quarter came in at $201.3 million versus the consensus estimate of $198.6 million.

GUIDANCE:

Harmony Biosciences sees FY2025 revenue of $820-860 million, versus the consensus of $844.4 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Quidel Corp (QDEL) Tops Q2 EPS by 17c, Lowers Guidance
• Cytokinetics (CYTK) Tops Q2 EPS by 13c
• Concentra Group Holdings Parent, Inc. (CON) Reports Q2 EPS of $0.52 ; Offers Guidance